Efficacy and Safety of Bococizumab (RN316/PF-04950615), a Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, in Hypercholesterolemic Japanese Subjects Receiving a Stable Dose of Atorvastatin or Treatment-Naive　― Results From a Randomized, Placebo-Controlled, Dose-Ranging Study ―-Reference-Cited by-同舟云学术

Efficacy and Safety of Bococizumab (RN316/PF-04950615), a Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, in Hypercholesterolemic Japanese Subjects Receiving a Stable Dose of Atorvastatin or Treatment-Naive　― Results From a Randomized, Placebo-Controlled, Dose-Ranging Study ―

Published:2017 Issue:10 Volume:81 Page:1496-1505
ISSN:1346-9843
Container-title:Circulation Journal
language:en
Short-container-title:Circ J

Author:

Yokote Koutaro¹,Kanada Shigeto²,Matsuoka Osamu³,Sekino Hisakuni⁴,Imai Keiji⁵,Tabira Junichi⁵,Matsuoka Nobushige⁵,Chaudhuri Sandip⁶,Teramoto Tamio⁷

Affiliation:

1. Department of Clinical Cell Biology and Medicine, Chiba University Graduate School of Medicine

2. Heishinkai Medical Group Incorporated

3. ToCROM Clinic, Heishinkai Medical Group Incorporated

4. Sekino Hospital

5. Development Japan, Pfizer Japan Inc.

6. Worldwide Research and Development, Pfizer Ltd

7. Teikyo Academic Research Center, Teikyo University

Publisher

Japanese Circulation Society

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://www.jstage.jst.go.jp/article/circj/81/10/81_CJ-16-1310/_pdf

Reference21 articles.

1. 1. Okamura T. Dyslipidemia and cardiovascular disease: A series of epidemiologic studies in Japanese populations. J Epidemiol 2010; 20: 259–265.

2. 2. Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, et al. Absolute risk of cardiovascular disease and lipid management targets. J Atheroscler Thromb 2013; 20: 689–697.

3. 3. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670–1681.

4. 4. Liang H, Chaparro-Riggers J, Strop P, Geng T, Sutton JE, Tsai D, et al. Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates. J Pharmacol Exp Ther 2012; 340: 228–236.

5. 5. Gumbiner B, Udata C, Joh T, Liang H, Wan H, Shelton DL, et al. The effects of single dose administration of RN316 (PF-04950615), a humanized IgG2a monoclonal antibody binding proprotein convertase subtilisin kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin (abstract). Circulation 2012; 126: A13322.

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Population PK/PD modeling of low‐density lipoprotein cholesterol response in hypercholesterolemic participants following administration of bococizumab, a potent anti‐PCSK9 monoclonal antibody;CPT: Pharmacometrics & Systems Pharmacology;2023-11-22

2. Regulatory Experience Assessing the Carcinogenic Potential of a Monoclonal Antibody Inhibiting PCSK9, Bococizumab, Including a 2-Year Carcinogenicity Study in Rats;International Journal of Toxicology;2022-06-07

3. Generation of a Novel High-Affinity Antibody Binding to PCSK9 Catalytic Domain with Slow Dissociation Rate by CDR-Grafting, Alanine Scanning and Saturated Site-Directed Mutagenesis for Favorably Treating Hypercholesterolemia;Biomedicines;2021-11-27

4. PCSK9 inhibitor and atorvastatin reduce cardiac impairment in ovariectomized prediabetic rats via improved mitochondrial function and Ca 2+ regulation;Journal of Cellular and Molecular Medicine;2020-07-06

5. Efficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update;Journal of Drug Assessment;2020-01-01